MISSISSAUGA, Ontario, June 18 /PRNewswire-FirstCall/ -- CardioGenics Holdings Inc. (BULLETIN BOARD: CGNH) , developer of the ultra-sensitive QL Care(TM) Point-Of-Care (POC) analyzer and products for the immunoassay segment of the In-Vitro Diagnostics market, announced a new corporate profile is available at http://www.cardiogenics.com/ataglance/ataglance.pdf
The 2-page profile was prepared by Redington, Inc., a leading life sciences financial communications firm, as part of its financial community programs for CardioGenics. It highlights the company's technology, development plans, clinical schedules, and market opportunities.
About CardioGenics Holdings Inc.
Through its operating subsidiaries, the Company develops ultra-sensitive analyzers and other products targeting the immunoassay segment of the Point-Of-Care IVD testing market. It has developed the QL Care(TM) Analyzer, a proprietary and ultra-sensitive Point-Of-Care immuno-analyzer, which will run a number of diagnostic tests under development, the first of which will be a series of cardiovascular diagnostic tests. As part of its core proprietary technology, the Company has also developed a proprietary method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improve instrument sensitivity to light. The Company's principal offices are located in Mississauga, Ontario, Canada. For more information please visit http://www.cardiogenics.com/.
Safe Harbor Statement - Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements, with words such as "anticipate, "believe," "expect," "future," "may," "will," "should," "plan," "projected," "intend," and similar expressions to identify forward-looking statements. These statements are based on the Company's beliefs and the assumptions it made using information currently available to it. Because these statements reflect the Company's current views concerning future events, these statements involve risks, uncertainties and assumptions. The actual results could differ materially from the results discussed in the forward-looking statements. In any event, undue reliance should not be placed on any forward-looking statements, which apply only as of the date of this press release. Accordingly, reference should be made to the Company's periodic filings with the Securities and Exchange Commission.
CardioGenics Holdings Inc.
CONTACT: Investor Relations: Redington Inc. - CardioGenics Desk,
+1-203-222-7399, or Wolfe Axelrod Weinberger Associates LLC - Robert Schatz,
+1-212-370-4500; Media Relations: The Investor Relations Group - Laura
Colontrelle, +1-212-825-3210
Web Site: http://www.cardiogenics.com/
